CER Daily Newsfeed

No More ‘Dabbling’: It’s Time to Embrace Value-Based Care

(2/25, Alex Azar, The Health Care Blog) comments “...I would say that around 20 percent of doctors are enthusiastic about the idea of VBC. Another 60 percent are what I would call ‘coachable’—meaning that they would be willing to make the shift if they were provided with sufficient education about VBC models and enabling technologies. That’s why the government needs to be a reliable partner in this transformation, providing stable, predictable frameworks that allow healthcare organizations to make long-term investments in care delivery reform. We need better data sharing, consistent quality metrics, and aligned incentives across programs. Only the federal government has the scope to support such large-scale change.” Full

Lawmakers Reintroduce Bill To Eliminate IRA’s ‘Pill Penalty’

(2/25, Maaisha Osman, Inside Health Policy) reports “A bipartisan group of lawmakers led by Rep. Greg Murphy (R-NC) reintroduced the Ensuring Pathways to Innovative Cures (EPIC) Act to counter what they call a ‘pill penalty’ in the Inflation Reduction Act (IRA), which they argue discourages research into small molecule drugs. The move follows a meeting last week between the brand-name drug lobby and President Donald Trump, where the group pledged to boost biopharmaceutical innovation and lower drug costs.” Subscription Required

UK: NICE Recommends Pharmaand’s Rubraca for Advanced Ovarian Cancer

(2/25, Emily Kimber, PMLiVE) reports “The National Institute of Health and Care Excellence (NICE) has recommended pharmaand’s (pharma&) Rubraca (rucaparib) as a first-line maintenance treatment option for a subset of advanced ovarian cancer patients.” Full

UK: NICE’s Prioritisation Process Explained – What Healthtech Developers Need to Know

(2/24, NICE Blog) comments “...If you're developing a healthtech product, understanding NICE's priorities is crucial. For 2024/25, NICE is focussing on innovations addressing: mental health, early cancer detection/diagnosis, diabetes, musculoskeletal conditions, women's health, respiratory conditions, neurology.” Full